BR112012011247A2 - assinatura para a diagnose da instabilidade genética e da agressividade do câncer de mama - Google Patents
assinatura para a diagnose da instabilidade genética e da agressividade do câncer de mamaInfo
- Publication number
- BR112012011247A2 BR112012011247A2 BR112012011247A BR112012011247A BR112012011247A2 BR 112012011247 A2 BR112012011247 A2 BR 112012011247A2 BR 112012011247 A BR112012011247 A BR 112012011247A BR 112012011247 A BR112012011247 A BR 112012011247A BR 112012011247 A2 BR112012011247 A2 BR 112012011247A2
- Authority
- BR
- Brazil
- Prior art keywords
- breast cancer
- aggressiveness
- polq
- genetic instability
- expression level
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 7
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 7
- 230000002068 genetic effect Effects 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 101100388061 Mus musculus Polq gene Proteins 0.000 abstract 3
- 101150098894 Polq gene Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000002493 microarray Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09306096A EP2322658A1 (en) | 2009-11-13 | 2009-11-13 | Signature for the diagnosis of breast cancer aggressiveness and genetic instability |
| PCT/EP2010/067401 WO2011058143A1 (en) | 2009-11-13 | 2010-11-12 | Signature for the diagnosis of breast cancer aggressiveness and genetic instability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012011247A2 true BR112012011247A2 (pt) | 2016-11-22 |
Family
ID=41647234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012011247A BR112012011247A2 (pt) | 2009-11-13 | 2010-11-12 | assinatura para a diagnose da instabilidade genética e da agressividade do câncer de mama |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8865408B2 (https=) |
| EP (2) | EP2322658A1 (https=) |
| CN (1) | CN102791879A (https=) |
| AU (1) | AU2010317877A1 (https=) |
| BR (1) | BR112012011247A2 (https=) |
| CA (1) | CA2780479A1 (https=) |
| ES (1) | ES2522992T3 (https=) |
| IL (1) | IL219697A0 (https=) |
| IN (1) | IN2012DN04944A (https=) |
| PT (1) | PT2499258E (https=) |
| WO (1) | WO2011058143A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2710142B1 (en) * | 2011-05-18 | 2017-04-26 | Centre National de la Recherche Scientifique (CNRS) | Signature for the diagnosis of cancer aggressiveness and genetic instability |
| EP2800821B1 (en) * | 2012-01-05 | 2016-11-16 | Centre National de la Recherche Scientifique (CNRS) | Signature for the diagnosis of lung cancer aggressiveness |
| CN102994627B (zh) * | 2012-06-21 | 2015-04-15 | 宁波海尔施基因科技有限公司 | 一种肿瘤用药个体化指导的检测方法 |
| US9157124B2 (en) | 2012-09-18 | 2015-10-13 | Institute For Cancer Research | Systems and methods for diagnosing a predisposition to develop colon cancer |
| FR3019821A1 (fr) * | 2014-04-14 | 2015-10-16 | Centre Nat Rech Scient | Nouveaux anticorps utiles pour le diagnostic et le pronostic du cancer |
| US10724100B2 (en) | 2015-09-16 | 2020-07-28 | Institute For Cancer Research | Systems and methods for treating patients having a genetic predisposition to develop prostate cancer |
| US10760081B2 (en) | 2015-10-07 | 2020-09-01 | New York University | Compositions and methods for enhancing CRISPR activity by POLQ inhibition |
| US20190055563A1 (en) * | 2015-10-19 | 2019-02-21 | Dana-Farber Cancer Institute, Inc. | Polymerase q as a target in hr-deficient cancers |
| CN106011262A (zh) * | 2016-06-29 | 2016-10-12 | 北京泱深生物信息技术有限公司 | 子宫内膜癌诊治标志物及其应用 |
| WO2020014297A1 (en) * | 2018-07-11 | 2020-01-16 | The Johns Hopkins University | Identification of dna polymerase theta inactivation mechanism |
| JP7689494B2 (ja) * | 2018-12-31 | 2025-06-06 | テンパス・エーアイ・インコーポレイテッド | 患者コホートの反応、増悪、および生存を予測し解析するための方法およびプロセス |
| US11875903B2 (en) | 2018-12-31 | 2024-01-16 | Tempus Labs, Inc. | Method and process for predicting and analyzing patient cohort response, progression, and survival |
| US11599800B2 (en) * | 2020-01-28 | 2023-03-07 | Color Genomics, Inc. | Systems and methods for enhanced user specific predictions using machine learning techniques |
| CN112725444A (zh) * | 2020-12-30 | 2021-04-30 | 杭州联川基因诊断技术有限公司 | 一种检测pgr基因表达的引物、探针、试剂盒和检测方法 |
| CN112646864A (zh) * | 2020-12-30 | 2021-04-13 | 杭州联川基因诊断技术有限公司 | 一种检测esr1基因表达的引物、探针、试剂盒和检测方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0408284B8 (pt) | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| KR20060123403A (ko) | 2003-12-01 | 2006-12-01 | 쿠도스 파마슈티칼스 리미티드 | 암 치료를 위한 ｄｎａ 손상 수복 억제제 |
| US20090081119A1 (en) | 2005-05-19 | 2009-03-26 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Inhibiting dna polymerase beta to enhance efficacy of anticancer agents |
| AT504702A1 (de) * | 2006-12-22 | 2008-07-15 | Arc Austrian Res Centers Gmbh | Set von tumormarkern |
| RU2446796C2 (ru) | 2006-12-26 | 2012-04-10 | Фармасайкликс, Инк. | Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии |
| DK2209375T3 (da) | 2007-10-03 | 2014-10-06 | Eisai Inc | Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf |
-
2009
- 2009-11-13 EP EP09306096A patent/EP2322658A1/en not_active Withdrawn
-
2010
- 2010-11-12 AU AU2010317877A patent/AU2010317877A1/en not_active Abandoned
- 2010-11-12 CA CA2780479A patent/CA2780479A1/en not_active Abandoned
- 2010-11-12 PT PT107767121T patent/PT2499258E/pt unknown
- 2010-11-12 WO PCT/EP2010/067401 patent/WO2011058143A1/en not_active Ceased
- 2010-11-12 CN CN2010800565327A patent/CN102791879A/zh active Pending
- 2010-11-12 BR BR112012011247A patent/BR112012011247A2/pt not_active IP Right Cessation
- 2010-11-12 ES ES10776712.1T patent/ES2522992T3/es active Active
- 2010-11-12 EP EP10776712.1A patent/EP2499258B1/en not_active Not-in-force
- 2010-11-12 IN IN4944DEN2012 patent/IN2012DN04944A/en unknown
-
2011
- 2011-05-18 US US13/110,749 patent/US8865408B2/en not_active Expired - Fee Related
-
2012
- 2012-05-09 IL IL219697A patent/IL219697A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2012DN04944A (https=) | 2015-09-25 |
| US8865408B2 (en) | 2014-10-21 |
| US20120021935A1 (en) | 2012-01-26 |
| AU2010317877A1 (en) | 2012-06-07 |
| EP2322658A1 (en) | 2011-05-18 |
| CA2780479A1 (en) | 2011-05-19 |
| ES2522992T3 (es) | 2014-11-20 |
| EP2499258A1 (en) | 2012-09-19 |
| IL219697A0 (en) | 2012-07-31 |
| CN102791879A (zh) | 2012-11-21 |
| EP2499258B1 (en) | 2014-08-06 |
| WO2011058143A1 (en) | 2011-05-19 |
| PT2499258E (pt) | 2014-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012011247A2 (pt) | assinatura para a diagnose da instabilidade genética e da agressividade do câncer de mama | |
| BR112014030750A2 (pt) | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar | |
| BR112014025269A2 (pt) | método para o prognóstico e tratamento de metástase de câncer | |
| Wang et al. | miR-133a represses tumour growth and metastasis in colorectal cancer by targeting LIM and SH3 protein 1 and inhibiting the MAPK pathway | |
| BR112013004673A8 (pt) | biomarcadores e métodos de tratamento. | |
| BR112015008255A2 (pt) | método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata | |
| MX391499B (es) | Metodos para predecir el desenlace clinico del cancer. | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| BR112013010023A2 (pt) | algoritimo aperfeiçoado para a detecção de diabetes | |
| BR112015023783A2 (pt) | método para diagnóstico e tratamento de metastase no câncer | |
| EP3236262A3 (en) | Surrogate functional diagnostics test for cancer | |
| BR112012024718A2 (pt) | método para a predição da recorrência de câncer da mama sob tratamento endócrino | |
| EP3739595A3 (en) | Gene expression profile algorithm and test for determining prognosis of prostate cancer | |
| WO2011095623A3 (en) | miRNA IN THE DIAGNOSIS OF OVARIAN CANCER | |
| ES2721639T3 (es) | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama | |
| BR112015031542A2 (pt) | métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores | |
| BR112012016376A2 (pt) | compostos de pirrolo-aminopirimida substituída | |
| MX343801B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. | |
| BR112014004336A2 (pt) | sistema e método para estimar a quantidade de interesse de um sistema de artéria / tecido / veia dinâmico | |
| BR112015004653A2 (pt) | método diagnóstico e terapêutico de câncer de moléculas alvo expressas em células-tronco cancerígenas | |
| BR112015022977A2 (pt) | métodos para predição de risco de metástase em melanoma cutâneo | |
| WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
| BR112013003793A2 (pt) | método de diagnóstico das doenças neurodegenerativas | |
| BR112015028997A2 (pt) | biomarcadores de expressão gênica e seu uso para a aplicação diagnóstica e prognóstica em pacientes potencialmente com necessidade de tratamento de inibidor de hdac | |
| MX2012001464A (es) | Sensibilidad a inhibidores de la angiogenesis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |